Case Report

Volume: 6 | Issue: 2 | Published: Feb 28, 2022 | Pages: 39 - 42 | DOI: 10.24911/ejmcr/173-1633552787

Mepolizumab-associated acute pancreatitis: a case report

Authors: Fiore Casale , Irum Jan

Article Info

Authors

Fiore Casale

University of New Mexico School of Medicine, Albuquerque, NM, USA

Irum Jan

University of New Mexico, Department of Internal Medicine, Albuquerque, NM, USA.

Publication History

Received: October 11, 2021

Revised: November 30, 2021

Accepted: December 18, 2021

Published: February 28, 2022

Abstract

Background: Drug hypersensitivity reactions commonly generate systemic syndromes but can also affect specific organs. Mepolizumab, a monoclonal antibody targeting interleukin-5, is a safe and effective Food and Drug Administration-approved biologic therapy for severe eosinophilic asthma. Case Presentation: A 49-year-old female developed acute pancreatitis complicated by acute hypoxic respiratory failure secondary to fluid overload. Following 72 hours of intravenous fluids and analgesic administration, an urticarial rash developed on the patient's trunk, raising concern for a drug-related exanthem. After medication reconciliation, it was deemed that she had a hypersensitivity reaction to mepolizumab. Conclusion: In several clinical trials, mepolizumab demonstrated few hypersensitivity reactions. This patient presentation highlights the importance of strong clinical suspicion for drug hypersensitivities, especially in patients failing to respond to the standard of care for common medical conditions.

Keywords: allergy, hypersensitivity, mepolizumab, pancreatitis, DRESS, green

Open access Creative Commons License

Pubmed Style

Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. EJMCR. 2022; 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787

Web Style

Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. https://ejmcr.com/articles/1282 [Access: December 25, 2024]. doi:10.24911/ejmcr/173-1633552787

AMA (American Medical Association) Style

Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. EJMCR. 2022; 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787

Vancouver/ICMJE Style

Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. EJMCR. (2022), [cited December 25, 2024]; 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787

Harvard Style

Fiore Casale, Irum Jan (2022) Mepolizumab-associated acute pancreatitis: a case report. EJMCR, 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787

Chicago Style

Fiore Casale, Irum Jan. "Mepolizumab-associated acute pancreatitis: a case report." 28 (2022), 39-42. doi:10.24911/ejmcr/173-1633552787

MLA (The Modern Language Association) Style

Fiore Casale, Irum Jan. "Mepolizumab-associated acute pancreatitis: a case report." 28.February 2022 (2022), 39-42. Print. doi:10.24911/ejmcr/173-1633552787

APA (American Psychological Association) Style

Fiore Casale, Irum Jan (2022) Mepolizumab-associated acute pancreatitis: a case report. , 28 (February 2022), 39-42. doi:10.24911/ejmcr/173-1633552787